A-TANGO Project
@a-tango.bsky.social
A-TANGO, an EU-funded Horizon2020 research consortium, is conducting Phase II #clinical studies of an innovative therapeutic strategy called G-TAK to fight advanced #cirrhosis and acute-on-chronic #LiverFailure, aka #ACLF.
🌐 https://a-tango.eu
🌐 https://a-tango.eu
What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
June 25, 2025 at 5:41 PM
What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
Join this exciting event!
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
May 28, 2025 at 8:21 PM
Join this exciting event!
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.
🗓️ What a fun #workshop at #EASLCongress 2025
🗓️ What a fun #workshop at #EASLCongress 2025
May 12, 2025 at 6:35 AM
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.
🗓️ What a fun #workshop at #EASLCongress 2025
🗓️ What a fun #workshop at #EASLCongress 2025
👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
May 10, 2025 at 10:41 AM
👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
May 9, 2025 at 11:06 PM
👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
May 9, 2025 at 10:03 PM
Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
May 9, 2025 at 3:05 PM
🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️!
#ACLF #cirrhosis #LiverFailure
#ACLF #cirrhosis #LiverFailure
May 8, 2025 at 10:10 PM
🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️!
#ACLF #cirrhosis #LiverFailure
#ACLF #cirrhosis #LiverFailure
📣 Today: #POSTER TOP-203, congrats 🥳
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
May 8, 2025 at 11:17 AM
📣 Today: #POSTER TOP-203, congrats 🥳
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
May 8, 2025 at 11:13 AM
📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
May 8, 2025 at 11:10 AM
📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
May 8, 2025 at 8:18 AM
TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
🎙️ Talking #ACLF with #patients!
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
May 7, 2025 at 7:46 PM
🎙️ Talking #ACLF with #patients!
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
👏 Our superstar Julian Pohl (Charité) is not only active in ACLF research but also brings 🧪 #suPAR & #MASLD into the spotlight! His poster WED-437 at #EASLCongress this year shows it can identify at-risk patients - a game-changer for non-invasive #diagnostics.
#LiverDisease #biomarkers #metabolism
#LiverDisease #biomarkers #metabolism
May 7, 2025 at 10:29 AM
👏 Our superstar Julian Pohl (Charité) is not only active in ACLF research but also brings 🧪 #suPAR & #MASLD into the spotlight! His poster WED-437 at #EASLCongress this year shows it can identify at-risk patients - a game-changer for non-invasive #diagnostics.
#LiverDisease #biomarkers #metabolism
#LiverDisease #biomarkers #metabolism
Have a glimpse at Wednesday's A-TANGO highlights at #EASLCongress in Amsterdam! 🤩
#ACLF #cirrhosis #PatientAdvocacy #PatientEvent #hepatology #GTAK #CombinatorialTherapy #MASLD #HealthcareDisparities
@europeliver.bsky.social
@easlnews.bsky.social
@rajivjalan.bsky.social
@korenjak.bsky.social
#ACLF #cirrhosis #PatientAdvocacy #PatientEvent #hepatology #GTAK #CombinatorialTherapy #MASLD #HealthcareDisparities
@europeliver.bsky.social
@easlnews.bsky.social
@rajivjalan.bsky.social
@korenjak.bsky.social
May 6, 2025 at 8:37 PM
Have a glimpse at Wednesday's A-TANGO highlights at #EASLCongress in Amsterdam! 🤩
#ACLF #cirrhosis #PatientAdvocacy #PatientEvent #hepatology #GTAK #CombinatorialTherapy #MASLD #HealthcareDisparities
@europeliver.bsky.social
@easlnews.bsky.social
@rajivjalan.bsky.social
@korenjak.bsky.social
#ACLF #cirrhosis #PatientAdvocacy #PatientEvent #hepatology #GTAK #CombinatorialTherapy #MASLD #HealthcareDisparities
@europeliver.bsky.social
@easlnews.bsky.social
@rajivjalan.bsky.social
@korenjak.bsky.social
Hope for #ACLF patients is on the horizon!
Join the A-TANGO Patient Event at #EASLCongress:
📅 Wed, 7 May 2025
🕑 14:00–15:00
📍 Room D202, Elicium Building, Level 2
Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes.
#LiverDisease
@europeliver.bsky.social
Join the A-TANGO Patient Event at #EASLCongress:
📅 Wed, 7 May 2025
🕑 14:00–15:00
📍 Room D202, Elicium Building, Level 2
Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes.
#LiverDisease
@europeliver.bsky.social
April 25, 2025 at 7:02 PM
Hope for #ACLF patients is on the horizon!
Join the A-TANGO Patient Event at #EASLCongress:
📅 Wed, 7 May 2025
🕑 14:00–15:00
📍 Room D202, Elicium Building, Level 2
Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes.
#LiverDisease
@europeliver.bsky.social
Join the A-TANGO Patient Event at #EASLCongress:
📅 Wed, 7 May 2025
🕑 14:00–15:00
📍 Room D202, Elicium Building, Level 2
Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes.
#LiverDisease
@europeliver.bsky.social
Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress
👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub
These short networking sessions are lots of fun! @easlnews.bsky.social
#hepatology #cirrhosis #ACLF
👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub
These short networking sessions are lots of fun! @easlnews.bsky.social
#hepatology #cirrhosis #ACLF
April 25, 2025 at 6:48 PM
Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress
👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub
These short networking sessions are lots of fun! @easlnews.bsky.social
#hepatology #cirrhosis #ACLF
👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub
These short networking sessions are lots of fun! @easlnews.bsky.social
#hepatology #cirrhosis #ACLF
👉 Please register now:
docs.google.com/forms/d/e/1F...
Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK
✔️ Food & drinks provided 🥂
docs.google.com/forms/d/e/1F...
Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK
✔️ Food & drinks provided 🥂
April 25, 2025 at 1:37 PM
👉 Please register now:
docs.google.com/forms/d/e/1F...
Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK
✔️ Food & drinks provided 🥂
docs.google.com/forms/d/e/1F...
Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK
✔️ Food & drinks provided 🥂